Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.

V, Shinde; S, Bhikha; Z, Hoosain; M, Archary; Q, Bhorat; L, Fairlie; U, Lalloo; MSL, Masilela; D, Moodley; S, Hanley; L, Fouche; C, Louw; M, Tameris; N, Singh; A, Goga; K, Dheda; C, Grobbelaar; G, Kruger; N, Carrim-Ganey; V, Baillie; Oliveira T, de; Koen A, Lombard; JJ, Lombaard; R, Mngqibisa; AE, Bhorat; G, Benadé; N, Lalloo; A, Pitsi; PL, Vollgraaff; A, Luabeya; A, Esmail; FG, Petrick; A, Oommen-Jose; S, Foulkes; K, Ahmed; A, Thombrayil; L, Fries; S, Cloney-Clark; M, Zhu; C, Bennett; G, Albert; E, Faust; JS, Plested; A, Robertson; S, Neal; I, Cho; GM, Glenn; F, Dubovsky; SA, Madhi

doi:10.1056/nejmoa2103055

Public

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.

Shared by NobleBlocks on May 5, 2021 • 12:00 AM UTC

Authors:

Shinde V

Bhikha S

Hoosain Z

Abstract

<h4>Background</h4>The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) pandemic. In a phase 1-2 trial involving healthy adults, the NVX-CoV2373 nanoparticle vaccine had an acceptable safet...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!